SRC and leukemia: The DNA methylation inhibitor 5-AzaC, which we find to strongly inhibit the ability of Src activation to promote cell invasion and motility phenotypes, has been approved for clinical use and shown to have benefit as an anti-cancer drug for treatment of certain classes of leukemias (30, 31).